Related Experiment Video

Updated: Jun 4, 2026

A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones
07:30

A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones

Published on: January 21, 2020

[Synthesis and structure-activity relationship of 13-hexylberberine analogues as CD36 antagonists]

Ying-hong Li1, Li Wang, Bin Hong

  • 1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|March 1, 2011
PubMed

Insights

Berberine analogues were synthesized and found to antagonize scavenger receptor CD36, a key factor in atherosclerosis. Compound 7g demonstrated the strongest activity, suggesting berberine derivatives as potential therapeutic agents for atherosclerosis.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Cardiovascular Research

Background:

  • Scavenger receptor CD36 mediates oxLDL uptake in macrophages, promoting foam cell formation and atherosclerotic lesion development.
  • CD36 is a potential therapeutic target for treating atherosclerosis.

Purpose of the Study:

  • To synthesize and evaluate berberine analogues as CD36 receptor antagonists.
  • To identify structural modifications that enhance CD36 antagonistic activity.

Main Methods:

  • Synthesis of 21 berberine derivatives based on a lead compound, 13-hexylberberine.
  • High-throughput screening (HTS) using an ELISA-like model to assess CD36 antagonistic activity.
  • Structure-activity relationship (SAR) analysis.
  • Secondary validation using an Sf9 insect cell HTS model.

Main Results:

  • 13-hexylberberine exhibited initial CD36 antagonistic activity.
  • Optimal activity was achieved by introducing substituents at specific positions on aromatic rings A and D.
  • Compound 7g, featuring a benzyloxyl group at the 9-position, displayed the highest CD36 antagonistic activity with an IC50 of 7.7 µmol/L.
  • Antagonistic activity of 7g was confirmed via a secondary HTS model.

Conclusions:

  • Berberine analogues represent a novel class of CD36 receptor antagonists.
  • These analogues hold promise as potential therapeutic agents for atherosclerosis.
  • Further research into berberine analogues for CD36 antagonism is warranted.

More Related Videos

Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine11:04

Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine

Published on: June 13, 2022

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...